2019-2020

Next generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46,XY DSD | Buonocore F, et al | Journal of the Endocrine Society | Dec. 2019

By nonacus-developer / August 25, 2023 / Comments Off on Next generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46,XY DSD | Buonocore F, et al | Journal of the Endocrine Society | Dec. 2019

Buonocore F, Clifford-Mobley O, King TF, Striglioni N, Man E, Suntharalingham JP, et al. Next-generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46, XY DSD. Journal of the Endocrine Society. 2019;12:2341-60. Nonacus Products: Custom panels Context The genetic basis of human sex development is slowly being elucidated, and >40…

Read More

Applications and analysis of targeted genomic sequencing in cancer studies | Bewicke-Copley F, et al | Computational and Structural Biotechnology Journal | Jan. 2019

By nonacus-developer / August 25, 2023 / Comments Off on Applications and analysis of targeted genomic sequencing in cancer studies | Bewicke-Copley F, et al | Computational and Structural Biotechnology Journal | Jan. 2019

Bewicke-Copley F, Kumar EA, Palladino G, Korfi K, Wang J. Applications and analysis of targeted genomic sequencing in cancer studies. Computational and structural biotechnology journal. 2019;17:1348-59. Nonacus Products: Germline Abstract Next Generation Sequencing has dramatically improved the flexibility and outcomes of cancer research and clinical trials, providing highly sensitive and accurate high-throughput platforms for large-scale…

Read More

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification | Ward DG, et al | BJU International | Sep. 2019

By nonacus-developer / August 25, 2023 / Comments Off on Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification | Ward DG, et al | BJU International | Sep. 2019

Ward DG, Gordon NS, Boucher RH, Pirrie SJ, Baxter L, Ott S, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification. BJU International. 2019;124(3):532-44. Nonacus products: Oncology Objectives To develop a focused panel of somatic mutations (SMs) present in the majority…

Read More

A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies | van Campen J, et al | British Journal of Haematology | Jul. 2020

By nonacus-developer / August 25, 2023 / Comments Off on A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies | van Campen J, et al | British Journal of Haematology | Jul. 2020

van Campen J, Silcock L, Yau S, Daniel Y, Ahn JW, Ogilvie C, et al. A novel non‐invasive prenatal sickle cell disease test for all at‐risk pregnancies. British journal of haematology. 2020;90(1):119-24. Nonacus Products: Prenatal healthcare Summary Sickle cell disease (SCD) is the most common genetic haematological disorder. The availability of non-invasive prenatal diagnosis (NIPD) is…

Read More

Non-invasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop | Clausen FB, et al | Vox sanguinis | May 2019

By nonacus-developer / August 25, 2023 / Comments Off on Non-invasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop | Clausen FB, et al | Vox sanguinis | May 2019

Clausen FB, Barrett AN, Noninvasive Fetal RHD Genotyping EQA2017 Working Group, Akkök CA, Armstrong‐Fisher S, Bergström KD, Boggione CT, Bævre MS, Choolani M, Christiansen M, Cotorruelo C. Noninvasive fetal RHD genotyping to guide targeted anti‐D prophylaxis-an external quality assessment workshop. Vox sanguinis. 2019;114(4):386-93.   Nonacus Products: Prenatal healthcare Background and Objectives Fetal RHD genotyping of cell-free fetal…

Read More

Non-invasive prenatal diagnosis of retinoblastoma inheritance by combined targeted sequencing strategies | Gerrish A, et al | Journal of Clinical Medicine | Oct. 2020

By nonacus-developer / August 25, 2023 / Comments Off on Non-invasive prenatal diagnosis of retinoblastoma inheritance by combined targeted sequencing strategies | Gerrish A, et al | Journal of Clinical Medicine | Oct. 2020

Gerrish A, Bowns B, Mashayamombe-Wolfgarten C, Young E, Court S, et al. Non-invasive prenatal diagnosis of retinoblastoma inheritance by combined targeted sequencing strategies. Journal of Clinical Medicine. 2020;9(11):3517. Nonacus Products: Prenatal healthcare Abstract Retinoblastoma, the most common childhood eye cancer, presents in two forms: heritable or sporadic. Heritable retinoblastoma is caused by a germline mutation…

Read More

PF513 mutations affecting the CREBBP hat domain predict response to MTOR inhibitors Everolimus and Temsirolimus in relapsed/refractory follicular lymphoma | Kumar E, et al | HemaSphere | Jun. 2019

By nonacus-developer / August 25, 2023 / Comments Off on PF513 mutations affecting the CREBBP hat domain predict response to MTOR inhibitors Everolimus and Temsirolimus in relapsed/refractory follicular lymphoma | Kumar E, et al | HemaSphere | Jun. 2019

Kumar E, Korfi K, Bewicke-Copley F, Witzig T, Leukam M, Ansell S, Scott J, Rallis K, Clear A, Efeyan A, Calaminici M. PF513 mutations affecting the crebbp hat domain predict response to motor inhibitors everolimus and temsirolimus in relapsed/refractory follicular lymphoma. HemaSphere. 2019;3(S1):209. Nonacus products: Oncology Abstract With an expanding array of novel treatment options…

Read More

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR | Ghorashian S, et al | Nature medicine | Sep. 2019

By nonacus-developer / August 25, 2023 / Comments Off on Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR | Ghorashian S, et al | Nature medicine | Sep. 2019

Nonacus Products: Cell3 Target: Oncology Abstract Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL), but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19− clones. Some factors, including the choice…

Read More